Lupin LtdQ1 FY27
Lupin Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹2,385P/E: 19.2Market Cap: ₹1.1L CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 4
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 4No information is provided regarding the same in the latest conference call.
Margin guidance
Category 3No information is provided regarding the same in the latest conference call.
3 more insights locked — sign up free to unlock
Fundraise plans
No information is provided regarding the same in the latest conference call.
Order book
No information is provided regarding the same in the latest conference call.
Capex plans
YesNo information is provided regarding the same in the latest conference call.
How does Lupin Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Lupin Ltd
Rev 4Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
Want more stocks like Lupin Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio